Equities researchers at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) in a research report issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.
Aptose Biosciences Stock Performance
Shares of NASDAQ APTO opened at $0.40 on Tuesday. Aptose Biosciences has a 52 week low of $0.33 and a 52 week high of $3.32. The stock has a market capitalization of $7.23 million, a P/E ratio of -0.09 and a beta of 1.26. The stock’s fifty day moving average is $0.38 and its 200 day moving average is $0.67.
Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15.
Institutional Inflows and Outflows
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Articles
- Five stocks we like better than Aptose Biosciences
- Investing In Automotive Stocks
- What a Trump Win Looks Like for the Market Now and Into 2025
- Find and Profitably Trade Stocks at 52-Week Lows
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.